Need access to NeoLink? Contact your Sales rep or our Client Services team at 866.776.5907, Option 3

June 11, 2025

 

 

As part of our ongoing commitment to advancing oncology diagnostics, we are optimizing our test menu to ensure you have access to the most clinically advanced solutions available.

Effective June 30, 2025, prognostic interpretation for select IHC stains will no longer be offered. These stains will continue to be available as technical component only. If interpretation is required, we encourage you to request a full consultation through our team of highly trained anatomic pathologists.

The full list of IHC test updates is available here.

For additional information on our IHC offerings and to view our complete testing portfolio, please visit NeoGenomics.com.

If you have any questions or concerns, contact your local NeoGenomics Sales Consultant or our Client Services team at 866.776.5907, option 3.

 

 

Upcoming changes to NeoNEWS

In recent weeks we conducted a survey to better understand how you engage with the content in NeoNEWS and how we can improve your experience. The results are in, and we are ready to move forward with a new approach. In response to your feedback, we will be revising the content and cadence of our newsletter to better reflect the needs of our readership.

Effective, Wednesday, July 2nd, for our Pathology clients, a new, improved bi-weekly email that will focus on test updates and new test announcements. For our Oncology clients, we will be providing relevant information on a quarterly basis. For those offices with an EHR integration, test updates that impact your business and integration will be shared as necessary.

If you have any question or concerns, please reach out to Client Services at 866.776.5907, Option 3.

 

Your acute myeloid leukemia (AML) patients may be eligible for the IDHNow for AML Sponsored Testing Program at no cost.

The IDHNow for AML Sponsored Testing Program provides no-cost rapid PCR testing to eligible patients with AML, leading to more targeted treatment options.

Patient Eligibility:

• Patient is newly diagnosed AML, and not previously treated
• Patient lives and receives treatment in the US or a US territory
• The patient does not have a known IDH1 mutation from a previous test
• The patient has not previously been tested under this program

To learn more and order today, please visit our website.